WO2002036106A3 - Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden - Google Patents

Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden Download PDF

Info

Publication number
WO2002036106A3
WO2002036106A3 PCT/EP2001/012511 EP0112511W WO0236106A3 WO 2002036106 A3 WO2002036106 A3 WO 2002036106A3 EP 0112511 W EP0112511 W EP 0112511W WO 0236106 A3 WO0236106 A3 WO 0236106A3
Authority
WO
WIPO (PCT)
Prior art keywords
anticholinergics
corticosteroids
compositions based
medicament compositions
novel medicament
Prior art date
Application number
PCT/EP2001/012511
Other languages
English (en)
French (fr)
Other versions
WO2002036106A2 (de
Inventor
Michel Pairet
Michael Paul Pieper
Christopher John Montagu Meade
Richard Reichl
Christel Schmelzer
Original Assignee
Boehringer Ingelheim Pharma
Michel Pairet
Michael Paul Pieper
Christopher John Montagu Meade
Richard Reichl
Christel Schmelzer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10062712A external-priority patent/DE10062712A1/de
Application filed by Boehringer Ingelheim Pharma, Michel Pairet, Michael Paul Pieper, Christopher John Montagu Meade, Richard Reichl, Christel Schmelzer filed Critical Boehringer Ingelheim Pharma
Priority to AU2002210575A priority Critical patent/AU2002210575A1/en
Priority to CA002436540A priority patent/CA2436540C/en
Priority to MXPA03003751A priority patent/MXPA03003751A/es
Priority to JP2002538918A priority patent/JP2004512359A/ja
Priority to EP01978463A priority patent/EP1333830A2/de
Publication of WO2002036106A2 publication Critical patent/WO2002036106A2/de
Publication of WO2002036106A3 publication Critical patent/WO2002036106A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Die vorliegende Erfindung betrifft neuartige Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden, Verfahren zu deren Herstellung sowie deren Verwendung bei der Therapie von Atemwegserkrankungen.
PCT/EP2001/012511 2000-10-31 2001-10-23 Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden WO2002036106A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002210575A AU2002210575A1 (en) 2000-10-31 2001-10-23 Novel medicament compositions based on anticholinergics and corticosteroids
CA002436540A CA2436540C (en) 2000-10-31 2001-10-23 Pharmaceutical compositions based on anticholinergics and corticosteroids
MXPA03003751A MXPA03003751A (es) 2000-10-31 2001-10-23 Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y corticoesteroides.
JP2002538918A JP2004512359A (ja) 2000-10-31 2001-10-23 抗コリン作用薬及びコルチコステロイドをベースとする新規医薬組成物
EP01978463A EP1333830A2 (de) 2000-10-31 2001-10-23 Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10054042 2000-10-31
DE10054042.2 2000-10-31
DE10062712.9 2000-12-15
DE10062712A DE10062712A1 (de) 2000-12-15 2000-12-15 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden

Publications (2)

Publication Number Publication Date
WO2002036106A2 WO2002036106A2 (de) 2002-05-10
WO2002036106A3 true WO2002036106A3 (de) 2002-09-19

Family

ID=26007540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012511 WO2002036106A2 (de) 2000-10-31 2001-10-23 Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden

Country Status (8)

Country Link
EP (1) EP1333830A2 (de)
JP (1) JP2004512359A (de)
AU (1) AU2002210575A1 (de)
CA (2) CA2733294C (de)
MX (1) MXPA03003751A (de)
PE (1) PE20020576A1 (de)
UY (1) UY26992A1 (de)
WO (1) WO2002036106A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
US7084153B2 (en) 2002-04-12 2006-08-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising steroids and a novel anticholinergic
DE10216429A1 (de) * 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040102469A1 (en) * 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
AU2005247105B2 (en) 2004-05-31 2010-11-11 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and corticosteroids
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
WO2006003078A1 (en) * 2004-06-29 2006-01-12 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and an anticholinergic
GB0523653D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
PE20081788A1 (es) 2007-02-19 2008-12-18 Cipla Ltd Combinaciones farmaceuticas
EP2100599A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
TR200909792A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum, kortikosteroid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR200909789A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum, budesonid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
TR200909793A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum, mometazon ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
EP2510928A1 (de) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium zur Verbesserung der Schlafqualität bei atemwegserkrankten Patienten
KR20230052903A (ko) 2020-07-31 2023-04-20 케모 리서치, 에스.엘. 흡입 투여를 위한 병용 요법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0504112A2 (de) * 1991-03-14 1992-09-16 Ciba-Geigy Ag Pharmazeutische Aerosolformulierungen
DE19835346A1 (de) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
WO2001078739A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and fluticasone proprionate
WO2001078736A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and rofleponide
WO2001078743A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and mometasone

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0504112A2 (de) * 1991-03-14 1992-09-16 Ciba-Geigy Ag Pharmazeutische Aerosolformulierungen
DE19835346A1 (de) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
WO2001078739A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and fluticasone proprionate
WO2001078736A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and rofleponide
WO2001078743A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and mometasone

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BALZANO G ET AL: "Effectiveness and acceptability of a domiciliary multidrug inhalation treatment in elderly patients with chronic airflow obstruction: metered dose inhaler versus jet nebulizer.", JOURNAL OF AEROSOL MEDICINE: THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR AEROSOLS IN MEDICINE. UNITED STATES 2000 SPRING, vol. 13, no. 1, April 2000 (2000-04-01), pages 25 - 33, XP001078735, ISSN: 0894-2684 *
MON F ET AL: "AEROSOL THERAPY IN ASTHMA", REVUE DES MALADIES RESPIRATOIRES, vol. 6, no. 3, 1989, pages 189 - 200, XP001078722, ISSN: 0761-8425 *
NISHIMURA KOICHI ET AL: "Additive effect of oxitropium bromide in combination with inhaled corticosteroids in the treatment of elderly patients with chronic asthma.", ALLERGOLOGY INTERNATIONAL, vol. 48, no. 1, March 1999 (1999-03-01), pages 85 - 88, XP001070756, ISSN: 1323-8930 *
PAVIA D ET AL: "Preliminary data from phase II studies with Respimat, a propellant-free soft mist inhaler.", JOURNAL OF AEROSOL MEDICINE: THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR AEROSOLS IN MEDICINE. UNITED STATES 1999, vol. 12 Suppl 1, 1999, pages S33 - S39, XP001078739, ISSN: 0894-2684 *
RUTGERS S R ET AL: "Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5'-monophosphate in COPD.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. UNITED STATES MAR 1998, vol. 157, no. 3 Pt 1, March 1998 (1998-03-01), pages 880 - 886, XP001078742, ISSN: 1073-449X *
VAN SCHAYCK C P ET AL: "Periodic treatment regimens with inhaled steroids in asthma or chronic obstructive pulmonary disease. Is it possible?", JAMA: THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. UNITED STATES 12 JUL 1995, vol. 274, no. 2, 12 July 1995 (1995-07-12), pages 161 - 164, XP001078744, ISSN: 0098-7484 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation

Also Published As

Publication number Publication date
CA2733294C (en) 2011-12-20
PE20020576A1 (es) 2002-08-09
MXPA03003751A (es) 2004-10-15
CA2436540C (en) 2008-01-29
JP2004512359A (ja) 2004-04-22
CA2436540A1 (en) 2002-05-10
WO2002036106A2 (de) 2002-05-10
AU2002210575A1 (en) 2002-05-15
EP1333830A2 (de) 2003-08-13
CA2733294A1 (en) 2002-05-10
UY26992A1 (es) 2002-06-20

Similar Documents

Publication Publication Date Title
WO2002036106A3 (de) Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden
AU2002337047A1 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
IL160440A0 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
AU2001262318A1 (en) Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament
ZA200200609B (en) Process for producing phenyl-alkanes compositions produced thereform, and uses thereof.
YU35503A (sh) Nove kompozicije lekova bazirane na solima tiotropijuma i solima salmeterola
AU2003206760A1 (en) Anticholinergic agents, method for producing the same and use thereof as medicaments
AU2001292320A1 (en) Benzylamine compound, process for producing the same, and intermediate therefor
WO1999054315A3 (de) Triazolone mit neuroprotektiver wirkung
WO2003037863A3 (de) Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung
WO2006015970A3 (en) Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
CA2462998A1 (en) Novel estrogenic compounds
WO2001049654A3 (de) Substituierte aminomethyl-phenyl-cyclohexanderivate
WO2001060343A3 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
MXPA03006648A (es) Compuestos antitombroticos, su preparacion y su utilizacion como medicamentos.
WO2001049651A3 (de) Aminomethyl-phenyl-cyclohexanonderivate
AU2003241785A1 (en) Intravenous composition, process for producing the same and preparation thereof
AU2003235114A1 (en) Stress inhibition composition, theanine-containing granule and process for producing the same
WO2004022542A3 (de) Substituierte 1,2,3,4-tetrahydrochinolinderivate
WO2002096799A3 (de) Siliciumsubnitrid, ein verfahren zur dessen hestellung und die verwendung des subnitrids
HU0000531D0 (en) Method for the correction of deuteranopia, filter used by the method and procedure for the production of the filter
WO2005047278A3 (de) Substituierte dihydrochinazoline ii
WO2006000009A3 (de) Lamellares eisen-iii-oxid
WO2004020623A3 (de) Verfahren zur herstellung von biologisch abbaubaren, funktionalisierten polymerpartikeln und deren verwendung als arzneimittelträger
WO2002074034A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und endothelinantagonisten

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001978463

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/003751

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2436540

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002538918

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001978463

Country of ref document: EP